News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Helix Biopharma Signs L-DOS47 Manufacturing Agreement With QSV Biologics, Ltd.
December 20, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Helix BioPharma Corp. (Helix; TSX, FSE: "HBP") today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Layoff Tracker
Intercept Fires 146 After Pulling Liver Disease Drug
December 17, 2025
·
97 min read
·
BioSpace Editorial Staff
Artificial intelligence
Roche Makes Good on Dealmaking Promise With $1.1B Caris Cancer Collab
December 17, 2025
·
1 min read
·
Tristan Manalac
Startups
Addition Debuts With $100M to Advance One-Time Therapies for Rare, Chronic Diseases
December 17, 2025
·
1 min read
·
Tristan Manalac
Vaccines
Pfizer CEO Blasts HHS’ Anti-Vaccine Policies as Revenue Outlook Dims
December 16, 2025
·
3 min read
·
Annalee Armstrong
